Disc Medicine bitopertin Phase 2 in EPP meets primary endpoint; key secondary misses significance

Disc Medicine, Inc.

Primary endpoint met: PPIX reduced 21.6% (20mg, p=0.003) and 40.7% (60mg, p<0.001) vs placebo +8.0%.
Key secondary (cumulative sunlight time) not significant: 175.1h (20mg), 153.1h (60mg) vs 133.9h placebo due to strong placebo response.
Phototoxic reactions with pain reduced 75% for 60mg (p=0.011) and 60% for 20mg (p=0.109).
Patient Global Impression of Change: 86% of 60mg completers rated 'much better' vs 50% placebo (p=0.022).
Bitopertin well tolerated, no SAEs; dizziness most common AE; two discontinuations at 60mg.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.